BD, Babson pair up to bring capillary blood draws to retail pharmacies

Red blood cells
BD and Babson Diagnostics said they are conducting clinical studies on their respective devices in real-world settings, while BD will shoulder the future regulatory submissions. (Pixabay)

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into pharmacies and retail settings.

The small-volume device, currently under development at BD, will be paired with Babson’s automated sample handling equipment and its upcoming diagnostic tests. The new long-term strategic agreement builds upon ongoing collaborations between the two companies in place since 2017.

"Patient expectations for health care are evolving, and patients are demanding care in more convenient settings,” BD’s president of life sciences, Patrick Kaltenbach, said in a statement. “With our specimen management innovations, we hope to revolutionize diagnostic testing to meet patient expectations with laboratory-quality tests that can be performed with small blood samples that do not require venipuncture.”

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

BD’s new specimen collection device will be designed for healthcare settings without trained phlebotomists, such as retail pharmacies as well as doctor’s offices, urgent care centers and nursing facilities—for both physician-ordered and self-ordered tests. Samples would then be collected and analyzed at a centralized CLIA laboratory.

RELATED : FDA clears GE spinout's less-painful blood draw device for testing A1c

"BD has been a leader in blood collection technology with a long history of global innovation," said Babson CEO Eric Olson. "The technology they are developing is critical to Babson's mission of making diagnostic blood testing more convenient and accessible without sacrificing accuracy or cost.”

Both companies said they are conducting clinical studies on their respective devices in real-world settings, while BD will shoulder the future regulatory submissions to the FDA and other international regulatory bodies.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.